Abstract | Anemia is a common comorbidity in children with chronic kidney disease (CKD). This condition is associated with multiple adverse clinical consequences and its management is a core component of nephrology care. Increased morbidity and mortality, increased risk of cardiovascular disease and decreased quality of life have been associated with anemia of CKD in children. Although numerous complex factors interact in the development of this anemia, erythropoietin deficiency and iron dysregulation (including iron deficiency and ironrestricted erythropoiesis) are the primary causes. In addition to iron supplementation, erythropoietin-stimulating agents (ESAs) can effectively treat this anemia, but there are important differences in ESA dose requirements between children and adults. Also, hyporesponsiveness to ESA therapy is a common problem in children with CKD. Although escalating ESA doses to target increased hemoglobin values in adults has been associated with adverse outcomes, no studies have demonstrated this association in children. The question of appropriate target hemoglobin levels in children, and the approach by which to achieve these levels, remains under debate. Randomized, controlled studies are needed to evaluate whether normalization of hemoglobin concentrations is beneficial to children, and whether this practice is associated with increased risks.
Introduction
A low hemoglobin level is a common comorbidity in children with chronic kidney disease (CKD) and is associated with multiple adverse clinical consequences, including mortality and the development and progres sion of cardiovascular risk factors, such as left ventricular hypertrophy (LVH). [1] [2] [3] Data from the literature indicate that uncontrolled anemia might be related to the progres sion of CKD as well as to an increased risk of hospitaliza tion. [4] [5] [6] [7] By contrast, increased hemoglobin values in children with CKD have been associated with improved healthrelated quality of life. 8 Thus, anemia manage ment is a core component of clinical pediatric nephro logy practice. Although many factors, such as shortened lifespan of red blood cells and iron deficiency, contribute to CKDassociated anemia, erythropoietin deficiency is the primary etiological factor.
Defining anemia in children with CKD is not straight forward and requires nuanced evaluation. Although normal hemoglobin values in both adults and children are known to vary based on age, race and sex, anemia management guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKFKDOQI) have not consistently recognized these demographic differences with regard to the evaluation and management of the anemia of CKD. [9] [10] [11] In adult patients with CKD, a fixed cutoff hemoglobin value of <110 g/l has been used to define anemia based on evi dence that outcomes are worse below this threshold. 12 Previous versions of the KDOQI anemia guidelines simply applied the adult hemoglobin cutoff to children, but this definition has been shown to substantially under estimate the prevalence of anemia in patients with CKD aged <18 years. 6 Given that children are likely to suffer differently from the effects of various CKD complica tions, including anemia, compared with adults, the utility of applying an adult hemoglobin treatment target to anemia management in children has been called into question. The most recent NKFKDOQI clinical practice guidelines use reference data from the National Health and Nutrition Examination Survey (NHANES) III to cite normative values in children, and recommend initi ating an evaluation for anemia when hemoglobin levels fall below the agespecific and sexspecific 5 th percentile value, although hemoglobin differences by race are still not taken into account (Table 1) . 12 The NHANES III survey data provide means, standard errors and percentile distributions for hematologic laboratory values collected from the US population between 1988 and 1994. 9 In this Review, we will explore the adverse associ ations of anemia of CKD in children, with attention to risk factors for its development. The etiological factors for this anemia will be discussed, along with therapeutic strategies and ongoing challenges in its management.
Morbidity and mortality
In children, as in adults, anemia is a common complica tion of CKD, which increases in prevalence with advanc ing stage of CKD. Data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) have demonstrated that the prevalence of anemia in children is 73% at stage 3 CKD, 87% at stage 4 and >93% at stage 5. 13 The anemia of CKD in children is associated with substan tial morbidity, an increased risk of cardiovascular disease, decreased quality of life and reduced exercise capacity. Unlike in adults, however, the requirements for linear growth and the increased prevalence of neuro cognitive problems in children with CKD might place them at dis proportionately increased risk for adverse effects related to persistent anemia. 14, 15 The anemia of CKD has been asso ciated with numerous adverse effects in children. Among adolescents maintained on hemo dialysis, decreased hemoglobin levels are a strong and independent predic tor of mortality. 3, 16 Anemia has also been associated with increased frequency of hospitalization and increased risk of mortality in children initiating dialysis. 17 An increased risk of hospitalization in children with anemia has been found not only in those on dialysis, but also among chil dren with predialysis CKD. Staples et al. demonstrated that anemia was associated with a nearly 40% increased risk of allcause hospitalization over 1 year of followup in children with CKD stage 2 and higher. 7 Anemia is known to increase the risk of develop ing LVH, which is prevalent in children with CKD and confers an increased risk for cardiovascular disease. 2, 18 This association has been noted not only in children on dialysis, but also among those with CKD stages 2-4. In a cross sectional analysis of the Chronic Kidney Disease in Children (CKiD) Cohort Study, decreased hemo globin values were associated with LVH independently of an eleva tion in blood pressure. 18 A European cohort study similarly noted an inverse correlation between hemoglobin concentration and left ventricular mass index in patients with early stages of CKD. 19 Decreased hemoglobin values were also associated with an increased risk of incident LVH in a longitudinal study of children with CKD. 1 Increasing evidence shows that anemia may be an indepen dent risk factor for the progression of CKD. A random ized, controlled trial conducted in adult patients with CKD found that early initiation of erythropoietin therapy in those with mild anemia seemed to delay the initiation of renal replacement therapy. 20 Furth et al. found that among adolescents (aged 11-18 years) with predialysis CKD, anemia was associated with an accelerated decline in glomerular filtration rate (GFR) compared with the decline rate in patients without anemia. 4 Data from the NAPRTCS CKD database have shown that anemia, independent of other factors, including underlying diag nosis, hypertension, stage of CKD and race, is associated with an increased risk of CKD progression (defined by reaching CKD stage 5). 21 Proposed mechanisms include renal tissue hypoxia, which stimulates production of pro fibrotic cytokines. Results of some erythropoietin trials in adults have suggested that correction of anemia may decrease the risk of CKD progression. 4, 5 Anemia also adversely affects the quality of life of pedi atric patients with CKD, including their neurocognitive development and exercise capacity. 12 Anemic adolescents with CKD have reported greater limitations in physical functioning, schoolwork, and activities with friends and family than their peers who do not have anemia, indepen dent of demographic characteristics includ ing sex, race and level of kidney function. 8 In terms of growth, a domain in which many children with CKD demonstrate impairment, early treatment of anemia with erythro poietin is associated with improvement. 22 
Pathogenesis of anemia in pediatric CKD
Although multiple complex factors interact in the develop ment of the anemia of CKD, decreased pro duction of erythropoietin by the diseased kidney is the primary defect (Box 1). In the majority of children with impaired renal function, erythropoietin production is inappropriately low at any given hemoglobin concentra tion. The mechanism for this decreased production has not been fully elucidated, although it is theorized that it could be a result of progressive loss of the erythropoietin producing peritubular fibroblastlike interstitial cells in the kidney. 23 Multiple other clinical factors might contribute to anemia among patients with CKD, which worsens with declining GFR. Iron deficiency is clearly associ ated with anemia, and in children with CKD might be a result of nutritional deficiency, poor enteral absorp tion of iron supplements, or chronic blood loss from frequent laboratory testing or in the context of chronic hemodialysis. Individual factors that cause anemia in CKD may have varying influence at different levels of GFR. At earlier stages of CKD, nutritional factors and iron deficiency may have a more prominent role in the etiology of anemia. By contrast, decreased production of erythropoietin by the diseased kidney might have a more substantial contribution at later stages of CKD.
Impaired erythropoiesis
Evaluating the adequacy of iron stores for erythro poiesis is complex in children with CKD. Ironrestricted erythro poiesis interferes with the production of healthy red blood cells by several mechanisms: absolute iron deficiency from inadequate intake or excessive loss, 'functional' iron deficiency (which refers to inadequate storage of iron to supply bone marrow stimulated with erythropoietin stimulating agents [ESAs]), and impaired iron traffick ing in the setting of inflammation. 24 In order to address this issue clinically, the presence of sufficient iron stores must be documented; in practice, serum levels of ferritin and transferrin saturation (TSAT) are most often used to assess iron availability for erythropoiesis. The KDOQI anemia guidelines recommend that during ESA treat ment, children with nondialysis CKD should achieve serum ferritin levels of >225 pmol/l and TSAT >20%, but there are no specific recommendations for target ferritin and transferrin levels for children not receiving treat ment with an ESA. 12 Clear evidence from the literature shows that normal values for iron para meters, including ferritin, transferrin and TSAT, vary with age in children, with reference values for all three generally increasing from infancy through adolescence. 25, 26 Although the KDOQI guidelines do recognize agespecific variations in hemoglobin in the recommendations for anemia evaluation, agespecific differences in iron para meters are not considered. Other, potentially more sensitive, indicators of iron status include reticulocyte hemoglobin content, which measures the immediate incorporation of iron into reticulo cytes, percentage of hypochromic red cells, defined as red blood cells with cellular hemo globin concentration <280 g/l, and serum soluble trans ferrin receptor, which is upregulated when iron stores are decreased. 25, 27, 28 Although these tests may provide better estimates of iron availability than ferritin or TSAT levels alone, none have attained widespread clinical use.
In clinical practice, serum levels of ferritin are con sidered to be reflective of iron stores in the body, and TSAT indicative of the amount of iron available to be transported to the bone marrow. TSAT is calculated from serum iron concentration divided by total ironbinding capacity, which is itself an indirect measure of trans ferrin levels. 28 However, ferritin and TSAT both have limita tions as indicators of iron stores in patients with CKD. Serum ferritin concentration is difficult to interpret as an indepen dent marker of iron status as it is also an acutephase reactant whose production is upregulated by inflammation. Although serum ferritin concentration is presumed to reflect a steadystate leakage of ferritin stored intra cellularly, serum levels may not accurately reflect total iron stores in the body; the process by which intracellular ferritin enters the circulation, from which it is directly measured, is not well understood. 28 Production of transferrin is also affected by inflamma tion, although, in contrast to the effect on ferritin, inflammation decreases transferrin production, resulting in misleadingly elevated TSAT values, even in the setting of ironrestricted erythro poiesis. 25, 28 In children specifically, serum iron levels have been shown to be inversely correlated with BMI zscore, although a clear relationship between BMI and ferritin has not been established. Obesityassociated variations in iron para meters might also be mediated by inflammation. 29 Inflammation Chronic inflammation is common in patients with CKD and is clearly associated with an increased risk of anemia. Proinflammatory cytokines, such as IL6 and tumor necrosis factor, are associated with anemia and contribute to decreased hematopoiesis by reducing iron availability and inhibiting the maturation of erythroid precursor cells in the bone marrow. 30 Increased levels of inflammatory markers have been detected in both adults and children with predialysis CKD, well before the initia tion of renal replacement therapy. [31] [32] [33] In a study of 64 children with CKD, nearly half had Creactive protein levels of >1 mg/l, indicating inflammation. 33 The anemia of inflammation has long been associ ated with elevated cytokine levels, but for many years the underlying mechanism of this anemia was not known. The antimicrobial and ironregulatory peptide hepcidin has emerged as the link between the inflamma tory response and the handling of iron for erythropoiesis. Hepcidin is an acutephase protein produced in the liver and is a nega tive regulator of iron utilization, which controls blood iron levels both by downregulating the absorption of iron in the intestine and by inhibiting the release of iron from iron storing reticulo endothelial cells. The mechanism for this process is through hepcidin induced down regulation of ferroportin, which is the major transmembrane iron transporter present on the surface of ironstoring cells. [34] [35] [36] Hepcidin binds directly to ferroportin channels, induc ing their internalization and degradation, effectively trapping iron within macro phages, hepatocytes and enterocytes (and reducing intestinal absorption). 34, 37 Iron is thus not made available for erythro poiesis. Hepcidin is freely filtered at the glomerulus and excreted by the kidney, and decreased hepcidin excretion in the context of decreased GFR is likely to contribute to anemia. 34 In addition, hepcidin has been shown to be directly induced by proinflammatory cytokines, including IL6, and is positively correlated with levels of Creactive protein in adult patients with CKD. [38] [39] [40] In a study of 48 children with CKD stages 2-4, 26 children on dialysis and 32 adults with CKD stages 2-4, serum hepcidin levels were com pared with those of healthy pediatric and adult controls. Hepcidin levels among children with both endstage renal disease and earlier stage CKD were significantly higher than levels in the healthy controls (P <0.001). 40 
Nutritional deficiencies
Aside from iron deficiency, there are multiple other nutritional deficiencies, including vitamin B 12 , folate and perhaps vitamin C, which could interfere with the produc tion of healthy mature red blood cells. Folate deficiency is common in children with CKD, and in a small cohort of children on hemodialysis oral folic acid supplemen tation resulted in an 11.4% mean increase in hemoglobin levels and decreased ESA dose requirement. 41 Carnitine deficiency might also decrease the survival of red blood cells in patients with CKD, as it leads to an increase in the membrane fragility of red blood cells. 42 Uremia and hyperparathyroidism Independent of nutritional factors, chronic uremia may also contribute to anemia. Uremic serum has been shown to shorten the survival of erythrocytes and might also stimulate hemolysis. 23, 43 Hyperparathyroidism has been associated with a poor response to erythropoietin and might be associated with decreased bone marrow pro duction of red blood cells as a result of myelofibrosis. 44, 45 However, although secondary hyperparathyroidism has been associated with anemia in adults, a study of chil dren on hemodialysis could not establish an association between parathyroid hormone levels and the achievement of adult hemoglobin target levels of 110 g/l. 46 
Risk factors
Multiple risk factors for the development of anemia in children with CKD have been identified, with the level of kidney function being one of the main risk factors. Data from the NAPRTCS cohort have consistently demon strated that the risk of anemia increases as CKD stage advances. 7, 13 A study performed within the CKiD cohort has shown that anemia is common in pediatric patients with CKD across all stages of CKD, but that hemo globin levels decline more rapidly as the GFR (determined by plasma disappearance of iohexol) falls below 43 ml/min/1.73 m 2 . 47 Treatment with anti hypertensive medica tions has also emerged as a risk factor for anemia in children with CKD, which may be attributable to the increased risk of anemia conferred by angiotensin convertingenzyme inhibitors. 13, 21, 48 Race is also recognized as a risk factor for anemia. Racial disparities in the prevalence of anemia among adults with CKD are well described, 49 and differences in hemoglobin by race have also been noted in the pediatric CKD population. Among children enrolled in the CKiD study, those of African American descent were noted to have average hemoglobin levels of 6 g/l lower than those of white children (95% CI -9 to -2 g/l), even after adjusting for other relevant characteristics, including GFR, use of iron supplementation and exogenous erythropoietin, and socioeconomic status. 11 
Therapeutic strategies
Therapy for anemia is a key factor for the reduction of morbidity and mortality in children with CKD. The two primary components of effective anemia management are treatment with an exogenous ESA and supplemental iron therapy. Adjunctive therapies can include treating other nutritional deficiencies and controlling bone mineral metabolism disorders. As recommended by the KDOQI guidelines, primary anemia prevention in children with CKD includes monitoring hemoglobin levels at least annually for detection of anemia, and initiating therapy for absolute iron deficiency as indicated. 12 
Treatment with ESAs
Recombinant human erythropoietin Most children with CKD and anemia will ultimately require treatment with an ESA. Recombinant human erythropoietin (rHuEPO), which may be administered intravenously or subcutaneously, effectively treats anemia both in children with predialysis CKD and those on main tenance dialysis. 12 Epoetin alfa is one of the most com monly used forms of rHuEPO in the USA, with epoetin beta more commonly used in Europe. Multiple other erythropoietin analogues are emerging and the pediat ric nephrologist must be constantly attuned to issues of safety and efficacy and how these agents act in children compared with adults. 50 In addition, it is important to note that the dosing requirements may differ substan tially between children and adults. In clinical practice, the rHuEPO 'starting dose' of 150 U/kg per week is based on data from an adult clinical trial. 51 Data from NAPRTCS have demonstrated that young children require higher rHuEPO doses than adults, ranging from 275 U/kg to 350 U/kg per week for infants, to 200-250 U/kg per week for older children. 45 An analysis performed by Bamgbola et al. among patients on chronic hemodialysis found that children and adolescents required higher absolute doses of rHuEPO than adults to maintain target hemo globin levels, in spite of the fact that mean body weight was lower in the children. 52 Unlike the dosing of many drugs in children, which is typically based on body size to account for a decreased volume of distribution in chil dren compared with adults, the rHuEPO doses required for successful achievement of target hemoglobin levels in pediatric patients seems to be independent of weight. 52, 53 Rather than determining rHuEPO doses in children based on body weight, it has been suggested that dosing should be based on hemoglobin deficit. In fact, there is evidence that an absolute rHuEPO dose of 1,000 U given intra venously can increase hemoglobin by 0.4 g/l both in children and adults. 51 The underlying mechanisms related to the increased requirement of rHuEPO seen in children have not been fully elucidated, but may be due to an increased presence of nonhematopoietic erythro poietin binding sites (for example, endothelial, kidney, skeletal muscle, brain, heart and retinal cells) in children, which may result in increased clearance of the drug. 45, 54 The major function of erythropoietin in these various cell types seems to be inhibition of apoptosis. 54 In addition, erythropoietin demand in children may be increased during periods of accelerated body growth, which clearly is more of a factor in younger children. 51 
Darbepoetin alfa
Darbepoetin alfa, an erythropoietin analogue with a longer halflife than rHuEPO, is now widely used in chil dren with CKD. The benefit of longer dosing intervals compared with those required for rHuEPO has made sub cutaneous darbepoetin alfa an attractive alternative for treating anemia in young children and is likely to improve adherence. Darbepoetin alfa may be administered intra venously or subcutaneously, and while drug clearance, halflife and bioavailability are similar for adults and chil dren regardless of route of administration, the absorp tion of the drug when given subcutaneously may be more rapid in children than in adults. 12 A randomized clinical trial conducted by Warady et al. in pediatric patients aged <18 years with CKD stages 4 or 5 (both dialysis and non dialysis CKD) demonstrated that darbepoetin alfa is as safe and effective for the correction of anemia as rHuEPO, with the added advantage of less frequent dosing. 55 A potential limiting factor in the use of darbepoetin alfa in pediatric patients is the reported discomfort associ ated with its administration. Schmitt et al. conducted a small randomized, controlled trial in children with endstage renal disease and demonstrated that subcutaneous injec tions of darbepoetin alfa were associated with signifi cantly higher pain perception in children than injections of subcutaneous epoetin beta (P <0.05). 56 Potential expla nations for this difference include differences in the types of buffer utilized in each preparation, with the epoetin beta preparation having a more physio logical pH than darbepoetin alfa. 56 
ESA hyporesponsiveness
Anemia that is hyporesponsive to ESA therapy is prev alent in children with CKD, although clarifying the issue of apparent ESA resistance versus inadequate ESA dosing can be challenging. Within the NAPRTCS cohort study, >20% of children with CKD stage 4 have been shown to have persistently low hemoglobin levels while on ESA treatment. 13 In most centers, the manage ment of ESA hyporesponsiveness involves escalation in ESA dose. 52 However, despite the absence of direct evi dence in the pediatric population, data from cohorts of adults with nondialysis CKD enrolled on the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial and the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial have caused concern among pediatric nephro logists regarding the appropriateness of this strategy. In the CHOIR trial, the ongoing escalation of ESA dose to target a hemoglobin level of 135 g/l was associated with an increased risk of cardiovascular events and death, with no concurrent improvement in quality of life. 57 Data from CREATE demonstrated that in adults with CKD stages 3 or 4, early correction of anemia with subcutaneous epoetin beta did not reduce risk of cardiovascular events, although increased hemoglobin targets were associ ated with improved physical functioning and quality of life. 58 Thus, the question of the appropriate target hemoglobin levels in children remains under debate. There are many reasons to advocate the normalization of hemoglobin levels in children with CKD, including optimization of growth, cognitive and cardiovascular function, and quality of life. Randomized, controlled studies in chil dren with CKD are clearly needed to evaluate whether targeting higher (and perhaps normalizing) hemo globin concentrations is associated with benefits to children, and more specifically whether the practice is associated with increased risks as has been demonstrated in adults. In the absence of such data, current recommendations are to target hemoglobin levels of 100-120 g/l in concordance with the FDA guidelines that apply to adults. 59 Aside from ESA dosing issues in children, there are patients in whom escalating ESA therapy does not correct hemoglobin levels to even a minimal goal, and these are patients often termed ESA hyporesponsive or 'resistant' . In adults with CKD, factors associated with ESA hyporesponsiveness include iron deficiency, chronic blood loss, chronic inflammation, oxidative stress and possibly hyperparathyroidism. 60 Bamgbola et al. have demonstrated that clinical factors found to be associated with a poor response to rHuEPO among children main tained on hemodialysis include chronic inflammation (as measured by the objective malnutrition-inflammation score), nutritional deficits (as measured by normalized protein catabolic rate), inadequate dialysis (as measured by urea reduction ratio and Kt/V), chronic blood loss and hyperparathyroidism. 52 Interestingly, age and sex were not found to be predictive of a poor response to therapy. This observation is in contrast to data in adults with CKD which suggest that older age, use of angiotensin convertingenzyme inhibitors and angiotensinreceptor blockers, high BMI and diabetes mellitus are predictors of a poor response. 61 Finally, pure red cell aplasia, second ary to neutralizing antibodies against erythropoietin, has been observed in patients with CKD treated with exo genous erythropoietin, and should be suspected in cases where hemoglobin levels are not responsive to increasing ESA dose or iron therapy. Diagnosis requires the detec tion of antierythropoietin antibodies, which are gen erally crossreactive with all forms of endogenous and exogenous erythropoietin, and treatment often involves immunosuppressive therapy. 45, 62 Iron therapy Supplemental iron therapy is another key component of the treatment of anemia of CKD in children. In children with CKD, iron deficiency, defects in iron handling and impaired production of erythropoietin are likely to have a substantial role in the development of anemia. However, little is known about iron status among children with nondialysis CKD. Although clinical practice recommen dations from KDOQI for the assessment of iron status and treatment targets do exist for children with CKD treated with an ESA, definitions of iron deficiency and distributions of indices of iron stores in children with mild to moderate CKD have not been well described. The KDOQI anemia guidelines recommend that during ESA treatment, children with nondialysis CKD achieve serum ferritin levels of >225 pmol/l and TSAT >20%. 12 However, there are no specific recommendations for target ferritin and TSAT levels for children not receiving treatment with an ESA. Patients with CKD often have normal or above normal ferritin values, low TSAT levels and persistent anemia, which might indicate inflammationmediated ironrestricted erythropoiesis. The normal or elevated ferritin value might not reflect total body iron stores that can be utilized appropriately for erythropoiesis, but might instead be a marker of inflammation.
Oral iron supplementation, although inexpensive and readily available, has limited efficacy for maintaining adequate iron stores for erythropoiesis owing to poor gastrointestinal absorption and issues of compliance. In addition, oral iron supplementation is often inadequate to keep up with chronic blood loss for children maintained on hemodialysis. Studies in children have confirmed the efficacy of intravenous iron preparations in children on hemodialysis in terms of improving measured iron stores, increasing serum hemoglobin levels and decreasing the dose of ESA required to maintain hemoglobin. 42, 63 In addi tion, administration of intravenous iron has been shown to result in increased hemoglobin levels in children with nondialysis CKD not maintained on an ESA. 64 Despite the benefits of intravenous iron, iron overload remains a considerable concern, with nephrologists often hesitating to administer additional iron to patients with serum ferri tin levels >1124-1798 pmol/l. Indeed, iron overload states might be associated with multiple adverse clinical effects in addition to causing increased oxidative stress. 65, 66 Thus, escalation of iron therapy in an attempt to overcome ESA hyporesponsiveness has practical limitations.
Conclusions
Anemia is prevalent among children with CKD, and is associated with multiple adverse outcomes. Erythropoietin deficiency and iron deficiency are the major underlying etiological factors, and are the mechanisms most likely to be targeted by current therapies. However, assess ing the iron status of patients can be challenging, espe cially in the setting of inflammation and ironrestricted erythro poiesis. With regard to questions concerning the safety and efficacy of escalating ESA doses in response to refractory anemia, there is a need for the identification of pathways beyond erythropoietin deficiency for the devel opment of other safe, nontoxic clinical interventions that could serve to adjunctively treat the anemia in children with CKD.
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